文献速递哮喘慢阻肺

哮喘与慢阻肺患者对维持吸入治疗的偏好:离散选择实验

Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment.
PubMed 文献 · Thorax · 2020-07-06

该离散选择实验纳入810例哮喘和1147例慢阻肺患者,评估其对吸入装置和药物属性的偏好。两组患者最看重起效时间从30分钟缩短至5分钟以及年急性加重次数从3次减至1次,且愿意以额外加重换取起效加快,或接受起效延迟以降低吸入糖皮质激素不良反应风险。每日一次给药、压力型吸入器及非胶囊启动方式也受偏好,但权重低于快速起效和减少加重。

要点

  • 哮喘和慢阻肺患者最重视吸入治疗快速起效和减少年急性加重次数。
  • 患者愿以增加一次急性加重换取起效时间缩短15分钟。
  • 患者愿接受起效延迟以换取吸入糖皮质激素不良反应风险降低。

核心结论

  • 哮喘和慢阻肺患者最重要的维持吸入治疗属性是快速缓解症状起效和较低的急性加重率。
  • 对吸入糖皮质激素安全性的担忧和装置便利性也影响偏好,但重要性较低。

研究设计与样本

  • 采用自填式网络离散选择实验,属性选择基于患者焦点小组和文献回顾。
  • 共纳入810例哮喘患者和1147例慢阻肺患者完成实验。

主要发现

  • 哮喘患者最看重起效时间从30分钟降至5分钟,其次是年急性加重从3次降至1次。
  • 慢阻肺患者对起效时间从30分钟降至5分钟和年急性加重从3次降至1次的重视程度相同。
  • 两组患者均愿意以额外一次急性加重换取起效时间缩短15分钟。
  • 两组患者均愿意接受起效时间延长以换取吸入糖皮质激素不良反应风险降低。
  • 两组患者均偏好每日一次而非每日两次给药、压力型吸入器而非干粉吸入器、非胶囊启动而非单次胶囊。

临床怎么用

  • 临床选择维持吸入治疗时应优先考虑起效速度和减少急性加重的效果。
  • 与患者沟通时需关注其对吸入糖皮质激素安全性和装置便利性的偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A variety of maintenance inhaler therapies are available to treat asthma and COPD. Patient-centric treatment choices require understanding patient preferences for the alternative therapies. METHODS: A self-completed web-based discrete choice experiment was conducted to elicit patient preferences for inhaler device and medication attributes. Selection of attributes was informed by patient focus groups and literature review. RESULTS: The discrete choice experiment was completed by 810 patients with asthma and 1147 patients with COPD. Patients with asthma most valued decreasing the onset of action from 30 to 5 min, followed by reducing yearly exacerbations from 3 to 1. Patients with COPD most and equally valued decreasing the onset of action from 30 to 5 min and reducing yearly exacerbations from 3 to 1. Both patients with asthma and patients with COPD were willing to accept an additional exacerbation in exchange for a 15 min decrease in onset of action and a longer onset of action in exchange for a lower risk of adverse effects from inhaled corticosteroids. Patients with asthma and COPD valued once-daily over twice-daily dosing, pressurised inhalers over dry powder inhalers and non-capsule priming over single-use capsules, although these attributes were not valued as highly as faster onset of action or reduced exacerbations. CONCLUSIONS: The most important maintenance inhaler attributes for patients with asthma and COPD were fast onset of symptom relief and a lower rate of exacerbations. Concerns about safety of inhaled corticosteroids and device convenience also affected patient preferences but were less important.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Tervonen T, Hawken N, Hanania NA, et al. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020. PMID: 32631932. doi:10.1136/thoraxjnl-2019-213974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。